Nektar Therapeutics (Nasdaq: NKTR) is expected to report Q2 earnings on Aug. 9. Here's what Wall Street wants to see:

The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Nektar Therapeutics' revenue will improve 15.8% and EPS will remain in the red.

The average estimate for revenue is $20.1 million. On the bottom line, the average EPS estimate is -$0.33.

Revenue details
Last quarter, Nektar Therapeutics booked revenue of $17.9 million. GAAP reported sales were 59% higher than the prior-year quarter's $11.3 million.

My

Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.

EPS details
Last quarter, non-GAAP EPS came in at -$0.34. GAAP EPS were -$0.36 for Q1 versus -$0.33 per share for the prior-year quarter.

Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.

Recent performance
For the preceding quarter, gross margin was 51.5%, 1,960 basis points worse than the prior-year quarter. Operating margin was -202.0%, 9,770 basis points better than the prior-year quarter. Net margin was -229.0%, 8,990 basis points better than the prior-year quarter.

Looking ahead
The full year's average estimate for revenue is $81.0 million. The average EPS estimate is -$1.42.

Investor sentiment
The stock has a two-star rating (out of five) at Motley Fool CAPS, with 192 members out of 220 rating the stock outperform, and 28 members rating it underperform. Among 49 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 37 give Nektar Therapeutics a green thumbs-up, and 12 give it a red thumbs-down.

Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Nektar Therapeutics is outperform, with an average price target of $11.00.

Over the decades, small-cap stocks like Nektar Therapeutics have provided market-beating returns, provided they're value-priced and have solid businesses. Read about a pair of companies with a lock on their markets in "Too Small to Fail: 2 Small Caps the Government Won't Let Go Broke." Click here for instant access to this free report.